



## **Living Cell Technologies Limited**

**ACN:** 104 028 042

**ASX:** LCT

**OTCQB:** LVCLY

### **ASX ANNOUNCEMENT**

## **March Quarterly Activities Report and Appendix 4C Cash Flow Statement**

---

**Sydney, Australia & Auckland, New Zealand – 28 April 2023** – Living Cell Technologies (ASX: LCT) (OTCQB: LVCLY) (“LCT” or “the Company”) is pleased to provide its quarterly activities report and appendix 4C for the period ended 31 March 2023.

### **NTCELL for Parkinson’s Disease**

The Company continued to optimise the NTCELL manufacturing protocol during the quarter in parallel with an ongoing and detailed assessment of the research and development (R&D) strategy implemented by the former Board and CEO.

Delays in transportation of sensitive living choroid plexus tissue from Invercargill, New Zealand to Sydney, Australia has been identified as a challenge affecting the quality of NTCELL product manufactured in Australia.

To address quality control issues associated with regulatory and shipping bottlenecks, LCT is exploring the engagement of a global Contract Research Organization (CRO) with infrastructure in New Zealand, to undertake manufacturing of NTCELL for the third clinical trial. NTCELL has previously been manufactured successfully in New Zealand where it was administered to clinical trial participants.

Additionally, the Board is considering a range of initiatives to expand and improve upon the NTCELL R&D program, including exploring additional indications that may be applicable to the Company’s encapsulation technology.

### **Corporate Activities**

As of 31 March 2023, LCT’s cash balance was A\$3.23M, and total cash outflow associated with operating activities was A\$0.56M. During the quarter, the Company completed a A\$0.75M share placement to clients of Alignment Capital (Alignment). Subsequent to the quarter, LCT’s entitlement offer of shares to all shareholders closed, raising an additional A\$0.691M. Alignment has informed LCT that they have received commitments from investors for the

entitlement offer shortfall of \$A0.693M, pursuant to the capital raising agreement between the parties.

### **Additional Project Assessments**

As outlined in the entitlement offer prospectus, LCT has budgeted for a substantial proportion of new capital raised to be allocated to the assessment and commencement of additional project opportunities to expand the Company's development pipeline. LCT has multiple projects under scientific and commercial assessment and has entered discussions with contract research organisations and academic institutions to assist in the advancement of new project assessments.

Furthermore, EAS Consulting Group (EAS) has been engaged to provide advice related to international regulatory affairs associated with pharmaceutical products. EAS is a leading provider of regulatory compliance solutions to industries regulated by the US Food and Drug Association (FDA).

**Authorised for release by the Board of Living Cell Technologies Limited.**

**Ends**

**For further information:** [www.lctglobal.com](http://www.lctglobal.com)

#### **Corporate and Media Enquiries**

Brad Dilkes  
Non-executive Director  
Mobile: +61 422 180 317  
[brad@lctglobal.com](mailto:brad@lctglobal.com)

### **About NTCELL**

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. Choroid plexus cells are naturally occurring 'support' cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with alginate to protect them from attack by the immune system. Therefore, no immunosuppressive regimen needs to be administered to recipients.

### **About Living Cell Technologies**

Living Cell Technologies Limited is a biotechnology company focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease. The Company is incorporated in Australia, with its operations based in Australia and New Zealand. LCT is listed on Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges.

For more information visit [www.lctglobal.com](http://www.lctglobal.com) or follow @lctglobal on Twitter, Facebook or LinkedIn.

## **Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

#### Name of entity

Living Cell Technologies Limited

#### ABN

14 104 028 042

#### Quarter ended ("current quarter")

31 March 2023

Consolidated statement of cash flows		Current quarter \$A	Year to date (9 months) \$A
<b>1.</b>	<b>Cash flows from operating activities</b>		
1.1	Receipts from customers	-	-
1.2	Payments for		
	research and development	(316,321)	(1,094,692)
	product manufacturing and operating costs	-	-
	advertising and marketing	(1,647)	(23,871)
	leased assets	-	-
	staff costs	(66,496)	(148,163)
	administration and corporate costs	(180,358)	(459,427)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	7,343	16,175
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
<b>1.9</b>	<b>Net cash from / (used in) operating activities</b>	<b>(557,479)</b>	<b>(1,709,978)</b>
<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire or for: entities	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A</b>	<b>Year to date (9 months) \$A</b>
	businesses	-	-
	property, plant and equipment	-	-
	investments	-	-
	intellectual property	-	-
	other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	businesses	-	-
	property, plant and equipment	-	-
	investments	-	-
	intellectual property	-	-
	other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	750,000	750,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(52,410)	(52,410)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A</b>	<b>Year to date (9 months) \$A</b>
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>697,590</b>	<b>697,590</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	3,085,658	4,238,857
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(557,479)	(1,709,978)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	697,590	697,590
4.5	Effect of movement in exchange rates on cash held	5,024	4,324
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>3,230,793</b>	<b>3,230,793</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts</b>	<b>Current quarter \$A</b>	<b>Previous quarter \$A</b>
5.1	Bank balances	1,218,597	1,079,402
5.2	Call deposits	2,012,196	2,006,256
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>3,230,793</b>	<b>3,085,658</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	66,496
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

<b>7. Financing facilities</b>	<b>Total facility amount at quarter end \$A</b>	<b>Amount drawn at quarter end \$A</b>
<p>Note: the term "facility" includes all forms of financing arrangements available to the entity.</p> <p>Add notes as necessary for an understanding of the sources of finance available to the entity.</p>		
7.1 Loan facilities		
7.2 Credit standby arrangements		
7.3 Other (please specify)		
<b>7.4 Total financing facilities</b>		
<b>7.5 Unused financing facilities available at quarter end</b>		
<p>7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.</p> <div style="border: 1px solid black; height: 100px; width: 100%;"></div>		

<b>8. Estimated cash available for future operating activities</b>	<b>\$A</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(557,479)
8.2 Cash and cash equivalents at quarter end (item 4.6)	3,230,793
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	3,230,793
<b>8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	5.8
<p>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</p>	
<p>8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:</p> <p>8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?</p> <div style="border: 1px solid black; padding: 5px;"> <p>Answer:</p> </div>	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

### Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 28 April 2023.....

Authorised by: By the Board.....

### Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been



properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively